Iqvia Holdings Inc (NYSE:IQV) insider Ari Bousbib sold 46,080 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $101.79, for a total value of $4,690,483.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ari Bousbib also recently made the following trade(s):

  • On Wednesday, November 1st, Ari Bousbib sold 46,080 shares of Iqvia stock. The stock was sold at an average price of $108.14, for a total value of $4,983,091.20.
  • On Monday, October 2nd, Ari Bousbib sold 46,080 shares of Iqvia stock. The stock was sold at an average price of $94.91, for a total value of $4,373,452.80.

Shares of Iqvia Holdings Inc (NYSE:IQV) traded down $0.27 during trading on Tuesday, reaching $101.00. 1,012,137 shares of the company traded hands, compared to its average volume of 1,504,491. The company has a market cap of $21,526.60, a P/E ratio of 23.35, a P/E/G ratio of 1.68 and a beta of 0.61. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.22 and a quick ratio of 1.22. Iqvia Holdings Inc has a one year low of $74.73 and a one year high of $110.67.

Iqvia (NYSE:IQV) last issued its earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05. The company had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.01 billion. Iqvia had a net margin of 0.58% and a return on equity of 12.60%. Iqvia’s quarterly revenue was up 77.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.00 EPS. analysts anticipate that Iqvia Holdings Inc will post 4.62 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on the company. Mizuho lowered Iqvia from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research note on Thursday, November 9th. SunTrust Banks restated a “hold” rating and issued a $114.00 price objective on shares of Iqvia in a research note on Friday, November 3rd. KeyCorp restated a “buy” rating and issued a $100.00 price objective on shares of Iqvia in a research note on Sunday, September 24th. Credit Suisse Group restated an “outperform” rating and issued a $110.00 price objective (up from $98.00) on shares of Iqvia in a research note on Monday, October 16th. Finally, Zacks Investment Research lowered Iqvia from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $105.23.

TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/05/iqvia-holdings-inc-iqv-insider-sells-4690483-20-in-stock.html.

About Iqvia

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Insider Buying and Selling by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.